(Q36960518)

English

Daclizumab

scientific article published on October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1 reference

Europe PubMed Central

Daclizumab (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

author name string

Marcus Mottershead

1

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

James Neuberger

2

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

language of work or name

0 references

publication date

1 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Expert Opinion on Biological Therapy

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1583-1596

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Daclizumab to prevent rejection after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Induction therapy with daclizumab in heart transplantation--how many doses?

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Pediatric liver transplantation with daclizumab induction

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1583

21 January 2018

Identifiers

10.1517/14712598.7.10.1583

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

release_i2ceiucly5fido335od6n2byki

1 reference

https://api.fatcat.wiki/v0/release/i2ceiucly5fido335od6n2byki

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36960518&oldid=1843836326"